Release Date: August 15, 2025
Expiration Date: August 15, 2026
Activity Overview
TROP2 is an actionable target in the treatment of triple-negative breast cancer (TNBC) owing to its high expression on tumor cells and low expression on healthy tissue. TROP2-targeting antibody-drug conjugates (ADCs) deliver potent cytotoxic chemotherapy to cancer cells. In this activity, three experts provide guidance on frequently asked questions regarding the use of ADCs in TNBC.
Target Audience
This activity is directed toward medical oncologists, advanced practice providers, nurses, pharmacists, and other health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Develop evidence-based strategies for integrating ADCs in the management of patients with metastatic TNBC
- Apply effective methods to mitigate adverse effects associated with ADCs in patients with metastatic TNBC
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine, Geffen School of Medicine
Program Director, Breast Medical Oncology
Assistant Chief, Translational Research, Division of Hematology-Oncology
Director, Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, CA
Disclosures: Consultant: Alyssum, Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer; Research (paid to institution): Alyssum, Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer.
Erika P. Hamilton, MD
Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, TN
Disclosures: Consultant (all payments to institution): Accutar Biotechnology, Arvinas, AstraZeneca, BeiGene, Circle Pharma, Daiichi Sankyo, Entos, Gilead Sciences, Halda Therapeutics, Incyclix Bio, IQVIA, Janssen, Jazz Pharmaceuticals, Jefferies LLC, Johnson and Johnson, Lilly, Medical Pharma Services, Mersana, Novartis, Pfizer, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla Pharma, Stemline Therapeutics, Tempus Labs, Zentalis Pharmaceuticals; Research Funding (all payments to institution): AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon Pharmaceuticals, Fujifilm, G1 Therapeutics, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, Inspirna, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, MabSpace Biosciences, MacroGenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, NuCana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Stemline Therapeutics, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks.
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio
The University of Texas MD Anderson Cancer Center
San Antonio, TX
Disclosures: Grant/Research Support: Eisai; Consultant: AstraZeneca, Genentech, Gilead, Lilly, Menarini, Pfizer; Speaker: AstraZeneca, Daiichi Sankyo, Gilead.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.